Replicor Publishes Data on HBV/HDV Treatment Showing Promising Results
Replicor Inc. has released data from its global compassionate access program for patients with chronic HBV/HDV infection. The program, conducted in collaboration with Dr. Marc Bourlière in France, involved the use of REP 2139-Mg in patients who had not responded to previous treatments like bulevirtide or lonafarnib and who suffered from cirrhosis or decompensated cirrhosis. The study included 33 patients across 16 sites in eight countries. Key findings highlighted the excellent safety profile of REP 2139-Mg, rapid symptom reversal, and high rates of HDV cure and HBV functional cure. The treatment also achieved the elimination of HBV and HDV from the liver in as little as 10 weeks. Dr. Andrew Vaillant, Replicor's CSO, emphasized the unique bifunctional nature of REP 2139, which targets HDV replication and subviral particle assembly, setting the stage for further trials in Europe. 
